Stock Financial Ratios, Dividends, Split History

SNCR / Synchronoss Technologies, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.00
Volume15,095,200.00
Market Cap ($M)295.20
Enterprise Value ($M)212.83
Book Value ($M)463.59
Book Value / Share9.27
Price / Book0.76
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 44,668,921
Common Stock Shares Outstanding 46,965,000
Common Shares Outstanding 42,171,671
Weighted Average Number Of Shares Outstanding Basic 44,669,000
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.17
Return on Assets (ROA)-0.10
Return on Equity (ROE)-0.18
Balance Sheet (mrq) ($M)
Assets982.90
Liabilities592.08
Quick Ration/a
Current Ratio3.43
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue0.00
Revenues402,361,000.00
Operating Income-129.60
Net Income-118.73
Earnings Per Share Basic-2.45
Earnings Per Share Diluted-2.45
Cash Flow Statement (mra) ($M)
Cash From Operations-18.25
Cash from Investing98.25
Cash from Financing98.25
Identifiers and Descriptors
CUSIP87157B103
Central Index Key (CIK)1131554
Related CUSIPS
087157B10 871578100 87157B903 871578103 87157B953

Split History

Stock splits are used by Synchronoss Technologies, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

Related News Stories

Synchronoss Technologies (SNCR) Soars: Stock Adds 5.5% in Session

2018-05-16 zacks
Synchronoss Technologies, Inc. (SNCR - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 45% in the past one-month time frame. (31-1)

BRIEF-Synchronoss Technologies Signs Agreement To Acquire Honeybee

2018-05-04 reuters
* SYNCHRONOSS TECHNOLOGIES INC - HAS SIGNED AN AGREEMENT TO ACQUIRE DIXONS CARPHONE PLC’S HONEYBEE SOFTWARE BUSINESS Source text for Eikon: Further company coverage: (1-3)

The Chefs' Warehouse, Inc. (CHEF) Sees Hammer Chart Pattern: Time to Buy?

2018-04-16 zacks
The Chefs' Warehouse, Inc. (CHEF - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because CHEF recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. (11-0)

Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?

2018-04-16 zacks
Collegium Pharmaceutical, Inc. (COLL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because COLL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. (10-0)

Alamo Group, Inc. (ALG) Sees Hammer Chart Pattern: Time to Buy?

2018-04-16 zacks
Alamo Group, Inc. (ALG - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because ALG recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. (15-0)

CUSIP: 87157B103